Comparative in vitro activity of ceftobiprole against Gram-positive cocci

International Journal of Antimicrobial Agents

Volumn 36, Issue 2, 2010, Pages 111-113

  Betriu, Carmen ^a   Culebras, Esther ^a   Gómez, María ^a   López Fabal, Fátima ^a   Rodríguez Avial, Iciar ^a   Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Coagulase negative staphylococci; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes

Indexed keywords

CEFTOBIPROLE; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; OXACILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; GRAM POSITIVE COCCI; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COAGULASE; HEMOLYSIN PROTEINS; HUMANS; MACROLIDES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 77953807325     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.04.003     Document Type: Article

References (14)

1. Lin G., Appelbaum P.C. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn Microbiol Infect Dis 2008, 60:233-235.
2. Rouse M.S., Steckelberg J.M., Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn Microbiol Infect Dis 2007, 58:363-365.
3. Zhanel G.G., Voth D., Nichol K., Karlowsky J.A., Noreddin A.M., Hoban D.J. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 2009, 64:364-369.
4. Bogdanovich T., Ednie L.M., Shapiro S., Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49:4210-4219.
5. Kosowska K., Hoellman D.B., Lin G., Clark C., Credito K., McGhee P., et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49:1932-1942.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
8. Jones R.N., Deshpande L.M., Mutnick A.H., Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002, 50:915-932.
9. Pillar C.M., Aranza M.K., Shah D., Sahm D.F. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 2008, 61:595-602.
10. Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008, 61:86-95.
11. Amsler K.M., Davies T.A., Shang W., Jacobs M.R., Bush K. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother 2008, 52:3418-3423.
12. Yun H.C., Ellis M.W., Jorgensen J.H. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn Microbiol Infect Dis 2007, 59:463-466.
13. Deresinski S.C. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008, 61:103-109.
14. Lodise T.P., Patel N., Renaud-Mutart A., Gorodecky E., Fritsche T.R., Jones R.N. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis 2008, 61:96-102.